Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM
Primary Purpose
Type 2 Diabetes
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Pramlintide acetate
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring triglycerides, endogenous, glucose, production
Eligibility Criteria
Inclusion Criteria:
- Type 2 DM study participants will be C-Peptide positive (levels > 0.3 nmol/L)
- Receiving insulin, metformin and/or sulfonylurea/glitinide.
- Maintained on stable anti-hypertensive medication.
- BMI < 52 kg/m2.
- T2DM for at least 3 months with HBA1C under 10%.
Exclusion Criteria:
- Receiving TZDs, exenatide, sitagliptin or pramlintide therapy.
- Receiving medications known to impair gastric emptying, intestinal motility, glucagon release or corticosteroids.
- Triglyceride levels > 400 mg/dl.
- BMI > 52 kg/m2.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
2
1
Arm Description
Type 2 diabetes patients will receive placebo with 3 meals in experimental period.
Type 2 Diabetes patient will receive Pramlintide with 3 meals in experimental period.
Outcomes
Primary Outcome Measures
Endogenous glucose production
Secondary Outcome Measures
Endogenous VLDL-Triglyceride production
Full Information
NCT ID
NCT00732147
First Posted
August 6, 2008
Last Updated
July 18, 2021
Sponsor
University of Maryland, Baltimore
Collaborators
Amylin Pharmaceuticals, LLC.
1. Study Identification
Unique Protocol Identification Number
NCT00732147
Brief Title
Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM
Official Title
Effects of Pramlintide on Endogenous Production of VLDL-Triglyceride and Glucose in the Post Prandial State in Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
July 2021
Overall Recruitment Status
Withdrawn
Why Stopped
Sponsor could not fund.
Study Start Date
April 2009 (undefined)
Primary Completion Date
April 2011 (Actual)
Study Completion Date
April 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Maryland, Baltimore
Collaborators
Amylin Pharmaceuticals, LLC.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Diabetes affects almost 21 million people in the United States. In this study we will test a drug called Pramlintide(Symlin), and see how it works to lower blood sugar and fat levels after a meal. Lowering high sugar levels and fat levels after a meal is very important in the prevention of the problems that persons with type 2 diabetes often encounter. Hypothesis is that Pramlintide will lower blood sugar and fat levels after a meal.
Detailed Description
A well recognized and troublesome feature of diabetes management is the exacerbated post prandial glucose elevations following a typical high fat meal. To date the mechanisms driving this increased post prandial glycemia are unclear. Pramlintide is believed to affect intermediary metabolism as well as nutrient absorption. The relative contributions from altered absorption and metabolism to the observed post prandial reductions in plasma glucose and TG concentrations remain uncertain, however. Combinations of radioactive and stable isotope labeling techniques are able to quantify the relevant fluxes of glucose and lipids in vivo in humans and are therefore able to provide quantitative answers to these questions.
Aims:
To determine the effects of Pramlintide on reducing endogenous production of very-low-density-lipoprotein (VLDL)-triglycerides(TG) following a high fat breakfast, lunch and dinner in patients with type 2 diabetes mellitus (T2DM). A triple isotope approach will be used to determine rate of appearance of (VLDL)-triglycerides following breakfast, lunch and dinner.
To compare the relative roles of slowed glucose absorption and reduced endogenous glucose production (glucagonstatic mechanism) in the glucose-lowering effects of Pramlintide in the post prandial state in patients with T2DM.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
triglycerides, endogenous, glucose, production
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
Participant
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Type 2 diabetes patients will receive placebo with 3 meals in experimental period.
Arm Title
1
Arm Type
Experimental
Arm Description
Type 2 Diabetes patient will receive Pramlintide with 3 meals in experimental period.
Intervention Type
Drug
Intervention Name(s)
Pramlintide acetate
Other Intervention Name(s)
Symlin
Intervention Description
120 micrograms given subcutaneously before each meal X 3.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
120 micrograms given subcutaneously before each meal x 3.
Primary Outcome Measure Information:
Title
Endogenous glucose production
Time Frame
18 hours
Secondary Outcome Measure Information:
Title
Endogenous VLDL-Triglyceride production
Time Frame
18 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Type 2 DM study participants will be C-Peptide positive (levels > 0.3 nmol/L)
Receiving insulin, metformin and/or sulfonylurea/glitinide.
Maintained on stable anti-hypertensive medication.
BMI < 52 kg/m2.
T2DM for at least 3 months with HBA1C under 10%.
Exclusion Criteria:
Receiving TZDs, exenatide, sitagliptin or pramlintide therapy.
Receiving medications known to impair gastric emptying, intestinal motility, glucagon release or corticosteroids.
Triglyceride levels > 400 mg/dl.
BMI > 52 kg/m2.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephen N. Davis, MD
Organizational Affiliation
Vanderbilt University
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM
We'll reach out to this number within 24 hrs